anti-Cancer/testis Antigen 2 (CTAG2) Antibodies

CTAG2 encodes an autoimmunogenic tumor antigen that belongs to the ESO/LAGE family of cancer-testis antigens. Additionally we are shipping Cancer/testis Antigen 2 Proteins (11) and and many more products for this protein.

list all antibodies Gene Name GeneID UniProt
CTAG2 30848 O75638
How to order from antibodies-online
  • +1 877 302 8632
  • +1 888 205 9894 (toll-free)
  • Order online

Top anti-Cancer/testis Antigen 2 Antibodies at

Showing 10 out of 40 products:

Catalog No. Reactivity Host Conjugate Application Images Quantity Supplier Delivery Price Details
Human Rabbit Un-conjugated IF (p), IHC (p), WB Formalin-fixed and paraffin: human gastric carcinoma labeled with Anti-CTAG2 Polyclonal Antibody, Unconjugated at 1:200 followed by conjugation to the secondary antibody and DAB staining 100 μL Log in to see 3 to 7 Days
Human Rabbit Un-conjugated IHC (p), WB CTAG2 Antibody (Center) (ABIN657689) western blot analysis in U251 cell line lysates (35 µg/lane). This demonstrates the CTAG2 antibody detected the CTAG2 protein (arrow). 400 μL Log in to see 10 to 11 Days
Human Mouse Un-conjugated ELISA, WB Detection limit for recombinant GST tagged CTAG2 is approximately 0.1 ng/mL as a capture antibody. 0.1 mg Log in to see 8 to 11 Days
Human Rabbit Alexa Fluor 350 IF (p)   100 μL Log in to see 14 to 21 Days
Human Rabbit Alexa Fluor 488 IF (p)   100 μL Log in to see 14 to 21 Days
Human Rabbit Alexa Fluor 555 IF (p)   100 μL Log in to see 14 to 21 Days
Human Rabbit Alexa Fluor 594 IF (p)   100 μL Log in to see 14 to 21 Days
Human Rabbit Alexa Fluor 647 IF (p)   100 μL Log in to see 14 to 21 Days
Human Rabbit Cy3 IF (p)   100 μL Log in to see 14 to 21 Days
Human Rabbit Cy5 IF (p)   100 μL Log in to see 14 to 21 Days

CTAG2 Antibodies by Reactivity, Application, Clonality and Conjugate

Attributes Applications Host Clonality Conjugate
Human , ,
, , , , , , , , , , , , , , , ,

More Antibodies against Cancer/testis Antigen 2 Interaction Partners

Human Cancer/testis Antigen 2 (CTAG2) interaction partners

  1. The tumor suppressor function of LSAMP (show LSAMP Antibodies) is most likely exerted by reducing the proliferation rate of the tumor cells, possibly by indirectly upregulating one or more of the genes HES1, CTAG2 or KLF10 (show KLF10 Antibodies).

  2. NYESO-1/LAGE-1s and PRAME (show PRAME Antibodies) are targets for antigen specific T cells in chondrosarcoma following treatment with 5-Aza-2-deoxycitabine

  3. LAGE-1a and NY-ESO-1 (show CTAG1B Antibodies) homology cannot be easily exploited in an anti-NY-ESO-1 (show CTAG1B Antibodies) vaccine given the low frequency of protein expression detected by IHC or serum analysis.

  4. Spontaneous LAGE-1-specific CD4 (show CD4 Antibodies)-positive T cells isolated from patients with advanced LAGE-1-positive/NY-ESO-1 (show CTAG1B Antibodies)-positive melanoma are directed against three promiscuous and immunodominant epitopes.

  5. CD4 (show CD4 Antibodies)+ T cell clones specific for alternatively translated tumor antigen CAMEL have been isolated from the peripheral blood of a melanoma patient; CAMEL(81-102) is described as a naturally processed epitope recognized and presented by HLA-DR11 (show WDR11 Antibodies) and HLA-DR12.

  6. Data showed aberrant expression of NY-ESO-1 (show CTAG1B Antibodies) and LAGE-1 by IHC/RT-PCR in a significant proportion of epithelial ovarian cancer patients.

  7. Data support the immunogenicity of NY-ESO-1 (show CTAG1B Antibodies)/LAGE-1 ORF2 gene products and clearly demonstrate their capability to stimulate T-helper 1 type CD4 (show CD4 Antibodies)+ T cells.

  8. LAGE-1 expression was more frequently found in squamous cell carcinoma than in adenocarcinoma.

  9. Isolation of CD4 (show CD4 Antibodies)+ T cell clones from T cell cultures of two healthy donors leads to identification of four naturally processed HLA-DR-binding CAMEL epitopes, interesting peptides to investigate for future cancer immunotherapy.

  10. LAGE-1 expression was detected in esophageal cancer by cDNA RDA. LAGE-1 might have the potential to be a target antigen for anti-tumoral immunotherapy in esophageal cancers because of its tumor-specific expression similar to that of MAGE (show MAGEB10 Antibodies)-A1.

Cancer/testis Antigen 2 (CTAG2) Antigen Profile

Protein Summary

This gene encodes an autoimmunogenic tumor antigen that belongs to the ESO\\/LAGE family of cancer-testis antigens. This protein is expressed in a wide array of cancers including melanoma, breast cancer, bladder cancer and prostate cancer. This protein is also expressed in normal testis tissue. An alternative open reading frame product of this gene has been described in PMID 10399963. This alternate protein, termed CAMEL, is a tumor antigen that is recognized by melanoma-specific cytotoxic T-lymphocytes. Alternate splicing results in multiple transcript variants.

Gene names and symbols associated with CTAG2

  • cancer/testis antigen 2 (CTAG2) antibody
  • CAMEL antibody
  • CT2 antibody
  • CT6.2 antibody
  • CT6.2a antibody
  • CT6.2b antibody
  • ESO2 antibody
  • LAGE-1 antibody
  • LAGE2B antibody

Protein level used designations for CTAG2

CTL-recognized antigen on melanoma , LAGE-1a protein , autoimmunogenic cancer/testis antigen NY-ESO-2 , cancer/testis antigen 6.2 , cancer/testis antigen family 6, member 2a , cancer/testis antigen family 6, member 2b , l antigen family member 1

30848 Homo sapiens
Selected quality suppliers for anti-Cancer/testis Antigen 2 (CTAG2) Antibodies
Did you look for something else?